Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 213

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation

Open access
Biddlestone-Thorpe, Laura, Sajjad, Muhammad, Rosenberg, Elizabeth, Beckta, Jason M., Valerie, Nicholas C.K., Tokarz, Mary, Adams, Bret R., Wagner, Alison F., Khalil, Ashraf, Gilfor, Donna, Golding, Sarah E., Deb, Sumitra, Temesi, David G., Lau, Alan, O'Connor, Mark J., Choe, Kevin S., Parada, Luis F., Lim, Sang Kyun, Mukhopadhyay, Nitai D., Valerie, Kristoffer·2013·Clinical Cancer Research

Abstract

Purpose: Glioblastoma multiforme (GBM) is the most lethal form of brain cancer with a median survival of only 12 to 15 months. Current standard treatment consists of surgery followed by chemoradiation. The poor survival of patients with GBM is due to aggressive tumor invasiveness, an inability to remove all tumor tissue, and an innate tumor chemo- and radioresistance. Ataxia–telangiectasia mutated (ATM) is an excellent target for radiosensitizing GBM because of its critical role in regulating the DNA damage response and p53, among other cellular processes. As a first step toward this goal, we recently showed that the novel ATM kinase inhibitor KU-60019 reduced migration, invasion, and growth, and potently radiosensitized human glioma cells in vitro. Experimental Design: Using orthotopic xenograft models of GBM, we now show that KU-60019 is also an effective radiosensitizer in vivo. Human glioma cells expressing reporter genes for monitoring tumor growth and dispersal were grown intracranially, and KU-60019 was administered intratumorally by convection-enhanced delivery or osmotic pump. Results: Our results show that the combined effect of KU-60019 and radiation significantly increased survival of mice 2- to 3-fold over controls. Importantly, we show that glioma with mutant p53 is much more sensitive to KU-60019 radiosensitization than genetically matched wild-type glioma. Conclusions: Taken together, our results suggest that an ATM kinase inhibitor may be an effective radiosensitizer and adjuvant therapy for patients with mutant p53 brain cancers. Clin Cancer Res; 19(12); 3189–200. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-12-3408

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 213

Metadata

Authors
Biddlestone-Thorpe, L., Sajjad, M., Rosenberg, E., Beckta, J. M., Valerie, N. C. K., Tokarz, M., Adams, B. R., Wagner, A. F., Khalil, A., Gilfor, D., Golding, S. E., Deb, S., Temesi, D. G., Lau, A., O'Connor, M. J., Choe, K. S., Parada, L. F., Lim, S. K., Mukhopadhyay, N. D., & Valerie, K.
Venue
Clinical Cancer Research
Published
2013-06-13
Volume
19
Issue
12
Pages
3189-3200
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2134457209
Cited by
213
References
11
FWCI
8.87
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-3408
The paper
Biddlestone-Thorpe, L., Sajjad, M., Rosenberg, E., Beckta, J. M., Valerie, N. C. K., Tokarz, M., Adams, B. R., Wagner, A. F., Khalil, A., Gilfor, D., Golding, S. E., Deb, S., Temesi, D. G., Lau, A., O'Connor, M. J., Choe, K. S., Parada, L. F., Lim, S. K., Mukhopadhyay, N. D., & Valerie, K. (2013). ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-3408

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.